Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MMP8 | P22894 | 4/20 | 0.40 |
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990208 | 0.79 | MMP2 (0.42) | MMP1MMP8MMP2CA2CA12 | |
| SCHEMBL8383247 | 0.78 | MMP2 (0.46) | MMP1MMP8MMP2CA2CA12 | |
| SCHEMBL3469330 | 0.75 | — | — | |
| SCHEMBL2916525 | 0.73 | MMP2 (0.42) | MMP1MMP8MMP2CA2CA12 | |
| SCHEMBL23488140 | 0.72 | MMP1 (0.37) | MMP1MMP8MMP2CA2CA12 | |
| SCHEMBL7643526 | 0.72 | LAP3 (0.52) | MMP1MMP8MMP2CA2CA12 | |
| SCHEMBL7643520 | 0.72 | LAP3 (0.52) | MMP1MMP8MMP2CA2CA12 | |
| SCHEMBL22856775 | 0.72 | MMP1 (0.37) | MMP1MMP8MMP2CA2CA12 | |
| SCHEMBL28434436 | 0.71 | — | — | |
| SCHEMBL28434433 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9930893-B2 | Inhibitors of DXP synthase and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-04-03 | — | — | US | disclosed |
| US-20150225430-A1 | INHIBITORS OF DXP SYNTHASE AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225430-A1 | INHIBITORS OF DXP SYNTHASE AND METHODS OF USE THEREOF | DHPS, FDPS, DPYD | MMP1 873/4885MMP8 1036/4885MMP2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.